Kim Murphy

Ms. Murphy brings a wealth of vaccine industry knowledge and experience that are highly-relevant to the Company’s strategic acquisition of Noachis Terra, as well as the development of the Company’s other product candidates. Ms. Murphy is an accomplished leader and medical-industry professional with substantial experience in the vaccine development arena, having previously served in a variety of vaccine-related leadership roles within GlaxoSmithKline plc (“GSK”). While with GSK, Ms. Murphy led the global influenza vaccine and pandemic preparedness businesses and was responsible for the strategic and prelaunch planning for multiple development-stage vaccines through commercialization. Ms. Murphy also managed a 2,000-employee vaccine development, sales, manufacturing, and distribution team and was responsible for the integration planning of GSK’s acquisition of Novartis AG’s vaccine division. Earlier in her career, she also worked in commercialization and marketing roles within Novartis Vaccines and Diagnostics Inc. and Merck & Co., Inc. Ms. Murphy has previously served in board and advisory roles for a privately-held vaccine development company, biotechnology industry groups, and academic and philanthropic societies. Ms. Murphy holds a B.A. degree in English from Old Dominion University and a M.B.A. degree in Marketing from Saint Joseph’s University.